Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 15/20 | 0.69 |
| ▸ | DHFR | P00374 | 4/20 | 0.69 |
| ▸ | FOLR1 | P15328 | 4/20 | 0.69 |
| ▸ | SLC19A1 | P41440 | 4/20 | 0.69 |
| ▸ | SLC46A1 | Q96NT5 | 4/20 | 0.69 |
| ▸ | GART | P22102 | 2/20 | 0.69 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.69 |
| ▸ | ATIC | P31939 | 1/20 | 0.69 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.69 |
| ▸ | FRK | P42685 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23117778 | 1.00 | TYMS (0.69) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL23117779 | 1.00 | TYMS (0.69) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL12180576 | 0.91 | TYMS (0.80) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL14008868 | 0.91 | TYMS (0.69) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL2610602 | 0.91 | TYMS (0.67) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL12232207 | 0.89 | GART (0.83) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL12314789 | 0.88 | TYMS (0.66) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL13524781 | 0.87 | TYMS (0.74) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL23752184 | 0.85 | TYMS (0.71) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL24629271 | 0.85 | TYMS (0.61) | TYMSDHFRFOLR1SLC19A1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245349-A1 | Process for the production of a pemetrexed salt | SCINOPHARM TAIWAN, LTD. | 2012-09-27 | — | — | US | disclosed |
| US-20110263851-A1 | PROCESSES FOR PREPARING INTERMEDIATES OF PEMETREXED | SICOR INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110201631-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING PEMETREXED | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-08-18 | — | — | US | disclosed |
| US-7994180-B2 | prepared, preferably in high purity, via a straight-forward process without the need for the purification of intermediates | SICOR INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994180-B2 | prepared, preferably in high purity, via a straight-forward process without the need for the purification of intermediates | SICOR INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20080146799-A1 | prepared, preferably in high purity, via a straight-forward process without the need for the purification of intermediates | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2008-06-19 | — | — | US | disclosed |
| US-20080146799-A1 | prepared, preferably in high purity, via a straight-forward process without the need for the purification of intermediates | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245349-A1 | Process for the production of a pemetrexed salt | DHFR, TYMS, MTHFD1 | TYMS 2/4885DHFR 1/4885FOLR1 21/4885 |
| US-20110201631-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING PEMETREXED | TYMP, TYMS, MTHFD1 | TYMS 2/4885DHFR 7/4885FOLR1 18/4885 |
| US-20110263851-A1 | PROCESSES FOR PREPARING INTERMEDIATES OF PEMETREXED | DPYD, TYMP, TYMS | TYMS 3/4885DHFR 5/4885FOLR1 48/4885 |
| US-20080146799-A1 | prepared, preferably in high purity, via a straight-forward process without the need for the purification of intermediates | TYMP, TYMS, DHFR | TYMS 2/4885DHFR 3/4885FOLR1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.